Search This Blog

Wednesday, October 4, 2023

Supreme Court Declines To Hear Appeal From Pro-Life Group That Secretly Filmed Abortion Workers

 by Samantha Flom via The Epoch Times (emphasis ours)

The U.S. Supreme Court declined to take up an appeal on Monday from a pro-life group that a jury found broke the law when it surreptitiously recorded Planned Parenthood employees.

The high court’s denial follows a 2022 ruling by the 9th U.S. Circuit Court of Appeals upholding most of the damages that a lower court awarded to Planned Parenthood in its lawsuit against the California-based Center for Medical Progress and its founder, David Daleiden.

The pro-life organization first made headlines in 2015 when it published online secretly recorded conversations with Planned Parenthood doctors and staff. The footage showed executives haggling over the pricing of aborted fetal body parts, sparking backlash and both congressional and state-level investigations of the abortion provider’s business practices.

The Center for Medical Progress’s scheme to obtain and publish the footage involved creating a fake company and fake identities. In its 2016 lawsuit, Planned Parenthood argued that the organization’s actions constituted fraud, trespassing, breach of contract, and a violation of the Racketeer Influenced and Corrupt Organizations Act.

Three years later, a jury sided with the abortion provider, finding that the pro-life group also violated the Federal Wiretap Act. Although the appeals court later overturned that aspect of the verdict, it accounted for less than $100,000 of the $2.4 million in damages—plus $13 million in attorneys’ fees—initially awarded.

Limitations on Free Speech

The Center for Medical Progress had argued before the 9th Circuit that its journalistic methods were protected under the First Amendment. But that argument was unanimously rejected by the appeals court, which said, “Invoking journalism and the First Amendment does not shield individuals from liability for violations of laws applicable to all members of society.”

In petitioning the Supreme Court, the pro-life group maintained (pdf) that Planned Parenthood, which did not sue for defamation, should nonetheless have to overcome the court’s previous strict limitations on what damages public figures may recover in relation to published speech.

In defense of its investigative methods, the Center for Medical Progress pointed to a similar undercover investigation conducted by Chris Wallace and published by ABC News’s “20/20.”

Using a fictitious name and fake credentials, ABC journalists met with fetal tissue vendors in the abortion industry,” the group noted. “Their three-month investigation revealed a host of illegal and unethical practices in the industry related to the sale of tissue from aborted babies.

“At the time—when it was not the focus of the investigation—Planned Parenthood praised ABC’s report and condemned the abortion provider who was its target,” the filing adds. “Gloria Feldt, then the president of Planned Parenthood, publicly stated, ‘Where there is wrongdoing, it should be prosecuted and the people who are doing that kind of thing should be brought to justice.’”

According to the Center for Medical Progress, Mr. Daleiden modeled his investigation on the ABC’s, using “nearly identical” methods and means.

The group also charged that Planned Parenthood had “euphemistically” labeled its losses as “infiltration” and “security damages” to circumvent the challenges presented by a defamation case—which would include showing that the published speech in question was false.

The complaint contains a list of grievances that are inextricably intertwined with CMP’s decision to publish videos detailing the results of its investigation. … Thus, even though PPFA ‘fail[ed] to file a defamation claim,’ it sought substantial ‘damages’ to reimburse it for expenses it voluntarily incurred to prevent similar investigative reports by others in the future, and to address the public’s perceived response to the video.”

Citing similar circuit court rulings that appear to contradict one another on whether the First Amendment’s protection applies in such cases, the Center for Medical Progress argued that the Supreme Court should settle the matter once and for all.

Planned Parenthood has denied selling the body parts of aborted babies for profit, maintaining that the Center for Medical Progress’s videos were deceptively edited as part of a smear campaign against the abortion provider.

The Supreme Court announced its rejection of the case on the first day of its 2024 term, which will run through June. In the coming months, the court is expected to hear cases involving second amendment rights, social media regulation, the power of federal agencies, a South Carolina redistricting dispute, and the availability of the abortion pill, among others

https://www.zerohedge.com/political/supreme-court-declines-hear-appeal-pro-life-group-secretly-filmed-abortion-workers

Mob of teen thieves strip shelves bare at CVS in Washington, DC

 A sticky-fingered mob of shoplifting teens has almost entirely cleaned out a Washington, DC-area CVS outlet — leaving the retailer’s shelves almost bare.

Startling images from inside the chain pharmacy in DC’s Columbia Heights neighborhood show row after row of empty shelves, thanks to about 45 youngsters who have been targeting the store, Fox affiliate WTTG-TV reported.

“When you walk into this CVS, you’d think the store is closing because there’s barely anything on the shelves,” WTTG reporter Sierra Fox said.

“In fact, the only items in stock are the ones that are locked up. I did ask an employee what gets stolen the most, and they just laughed and said, ‘Everything,'” she added.

According to store employees, the rowdy mob of minors routinely raid the store for chips, drinks and other items — and claim street vendors also pay the teens to pocket items for the store that they later sell at a profit on the sidewalk.

Meanwhile, the Columbia Heights store only has one security guard to keep an eye on the merchandise.

Employees at a CVS in the Columbia Heights neighborhood in Washington, DC, said dozens of teens routinely shoplift at the store, allegedly selling merchandise to nearby street vendors — leaving the shelves almost entirely bare.
FOX 5 DC
“When you walk into this CVS, you’d think the store is closing because there’s barely anything on the shelves,” WTTG reporter Sierra Fox said.
FOX 5 DC

“It makes me not want to shop there, to be honest,” customer Ilana Miller told the outlet.

“I just go in there and get my prescription and then when I need other things, I go elsewhere because there’s nothing there to get,” she said.

Constant shoplifting and flash mobs of thieves have put a dent in profits of some of the nation’s largest retailers, including CVS, Rite Aid and Target — with the big-box retailer recently announcing it was shutting down an East Harlem outlet and eight other stores due to heavy losses.

Customer Ilana Miller said the shelves are so bare from shoplifters that she typically picks up her prescriptions, then leaves “because there’s nothing there to get.”
FOX 5 DC
“The only items in stock are the ones that are locked up. I did ask an employee what gets stolen the most, and they just laughed and said, ‘Everything,'” Sierra Fox added.

“A lot of people can’t actually afford things in CVS,” DC resident Gerald Darling told WTTG.

“I’m not saying stealing has to be the solution to that,” he added. “However, I don’t know, maybe if the city could provide more accessible resources to unhoused or under-income folks who can provide them hair care, bodily care, hygiene care — that could be an option.”

https://nypost.com/2023/10/04/thieves-strip-shelves-bare-at-cvs-outlet-in-the-nations-capital/

MaxCyte prelims, guidance hit

 Preliminary Third Quarter 2023 Revenue

  • Total revenue of $7.8 – 8.0 million in the third quarter of 2023, a decrease of 25 -27% compared to the third quarter of 2022; the decline is due to continued reduced customer activity in the sector.
  • Core business revenue of $6.4 - 6.6 million in the third quarter of 2023, a decrease of 33 - 35% compared to the third quarter of 2022.
  • Strategic Partnership License (SPL) Program-related revenue of $1.4 million in the third quarter of 2023, compared to $0.8 million in the third quarter of 2022.

Updated 2023 Revenue Guidance

  • Total revenue now expected to be approximately $34 - 36 million for the year.
  • Core revenue now expected to be approximately $28 - 30 million for the year.
  • SPL Program-related revenue expected to be approximately $6 million for the year, consistent with prior guidance.

“Given the ongoing volatility in customer activity in the life science tools sector, and after reviewing third quarter preliminary revenue, we are providing shareholders with an update on our expected full year revenue performance. We have updated our total revenue and core revenue guidance for 2023 to reflect a more challenging operating environment, which we expect to persist at least through the remainder of the year,” said Doug Doerfler, President and Chief Executive Officer at MaxCyte.
“Processing Assembly (disposable) purchases in both Cell Therapy and Drug Discovery are not materializing as expected. In addition, we continue to see hesitancy in Cell Therapy instrument purchases by early-stage customers. We believe this customer activity is primarily the result of a depressed funding environment in the Cell and Gene Therapy sector and in the broader biotech industry, as well as customers’ higher levels of Processing Assembly inventory remaining from previous year purchases. Customers also continue to reprioritize their spending, which has resulted in an overall elongation or pause of certain preclinical and early clinical activity.”

Doug continued, “While we are disappointed with our 2023 revenues thus far, we remain optimistic about MaxCyte’s long-term prospects, business model and ability to deliver shareholder value as the cell therapy industry grows and we continue to execute on our strategy. We are prudently managing our costs amid the challenging industry environment and still expect to end the year with approximately $200 million in cash, which would be unchanged from our initial outlook at the beginning of the year. Our robust and expanding partnership portfolio, with 23 SPL agreements now in place, highlights MaxCyte’s premier cell engineering technology and expertise and supports the significant role we play in enabling a growing set of next-generation cell therapies. We note that a number of our customers are reaching important clinical and regulatory milestones with the support of our technology.”

MaxCyte’s third quarter results are preliminary and unaudited and subject to change in connection with the completion of MaxCyte’s quarterly closing process and review procedures. As a result, these preliminary results may differ from the actual results that will be reflected in MaxCyte’s consolidated financial statements for the quarter ended September 30, 2023, which are expected to be released on or about November 8, 2023.

Conference Call
MaxCyte will host a conference call today, Wednesday, October 4 at 4:30pm ET to discuss these preliminary revenue results. Interested parties may access the live teleconference by dialing (800) 715-9871 for domestic callers (U.S. toll-free), (646) 307-1963 for international callers (U.S. toll), +44.800.260.6466 for U.K. domestic callers (U.K. toll-free), or +44.20.3481.4247 for U.K. international callers (U.K. toll) followed by Conference ID: 9979719. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.

https://www.globenewswire.com/news-release/2023/10/04/2754944/0/en/MaxCyte-Announces-Preliminary-Third-Quarter-2023-Revenue-and-Updates-Full-Year-2023-Revenue-Guidance.html

Ozempic Is Causing ‘Slight Pullback’ by Shoppers, Walmart Says

 “We definitely do see a slight change compared to the total population, we do see a slight pullback in overall basket,” John Furner, the chief executive officer of Walmart’s sprawling US operation, said in an interview Wednesday. “Just less units, slightly less calories.”

The Bentonville, Arkansas-based retailer is studying changes in sales patterns using anonymized data on shopper populations. It can look at the purchasing changes among people taking the drug and can also compare those habits to similar people who aren’t taking the shots. Furner said it’s too early to draw any definitive conclusions about the appetite-suppressing drugs made by Novo Nordisk A/S, and similar medicines.

An increasing number of CEOs and investors are talking about how popular weight-loss drugs might change the economy and business. Earlier this week, the CEO of the maker of Pringles and Cheez-Its said the company is studying their potential impact on dietary behaviors.

“Like everything that potentially impacts our business, we’ll look at it, study it and, if necessary, mitigate,” Steve Cahillane, the CEO of Kellanova, said in an interview.

Walmart sells GLP-1 drugs, a category that includes Ozempic, through its pharmacies. In August, it said they were giving the retailer a revenue boost. US sales for those medicines increased 300% between 2020 and 2022, according to a recent report from Trilliant Health.

“We still expect food, consumables, and health and wellness primarily due to the popularity of some GLP-1 drugs to grow as a percent of total in the back half,” Walmart CEO Doug McMillon said on a call with analysts in August.

Strikes and the Impact on the Employment Report

 Workers on strike during the reference week are not counted as employed in the BLS employment report. Every month, on the Friday before the release of the employment report, the BLS releases the CES Strike Report showing the number of workers on strike during the reference period.


September StrikesClick on chart for larger image.

In September, 17,700 workers were on strike, mostly the now settled writers' strike.    Ended strikes give a boost to the employment report (this was a few thousand in September).


This number will be closely watched in October with the UAW strike.  The Kaiser strike (75,000 workers) is scheduled for just 3 days and will not impact the October employment report.

Note that the reference week for October is next week.

A good example of the impact of a strike on the employment report is the AT&T strike in 1983 when 675,000 workers were on strike in August 1983.  The BLS reported job losses of over 300 thousand in August, and then a gain of over 1.1 million in September when the workers returned.

The Strike Report will be important to check on Friday, October 28th.

GM Taps JPMorgan For $6 Billion Credit Line As Strikes Hit Third Week

 The strike by the United Auto Workers union against Detroit's three major automakers (Ford Motor Co., General Motors Co., and Chrysler-parent Stellantis) entered its third week on Monday, with seemingly little progress made. Notably, General Motors has activated a multi-billion dollar credit line from JPMorgan Chase Bank, an indication the automaker might be bracing for the strike to continue for an extended period. 

GM issued a filing on Wednesday morning detailing how it "entered into a new 364-Day Revolving Credit Agreement with JPMorgan Chase Bank, NA" for "an available borrowing capacity of $6 billion" that matures on Oct. 1, 2024. 

Bloomberg pointed out GM's total automotive liquidity was around $39 billion, and there is no fear of the automaker depleting funds anytime soon. However, it noted, "But the new credit line is a sign GM may be buckling in for a prolonged work stoppage by the United Auto Workers." 

Last Friday, UAW boss Shawn Fain launched another wave of strikes against Ford and GM for failing to agree on a new four-year labor deal. Fain said Stellantis avoided additional strikes because of meaningful progress on a new labor contract.

On Tuesday, Ford and GM announced another 500 workers were laid off at four Midwestern plants because of the worsening impacts of labor actions. The Wall Street Journal said, "With the layoffs disclosed by GM and Ford on Monday, more than 6,000 factory workers are off the job because of spillover effects from the strike. That figure includes several suppliers who have cited furloughs directly tied to the walkouts." 

As of mid-week, about 25,000 out of 146,000 UAW workers are on strike at plants operated by the three automakers. UAW Boss Fain will likely provide another update on Friday. 

A recent report by Morgan Stanley's auto strategist, Adam Jonas, said automakers stand to lose $250 million in lost profit each day of the strike:

"The value of N. American light production of the D3 (F, GM, STLA collectively) is approximately $750mm per day (approx. 15k units per day). Applying slightly more than a 30% decremental (yes, mix is that high) implies around $250mm of lost profit per day (assuming 100% of production impacted)."

If GM pulling the credit line with JPM is any indication of what's to come, it appears the automaker is preparing for strikes to extend. 

https://www.zerohedge.com/markets/gm-taps-jpm-6-billion-credit-strikes-hit-third-week

'CDC Proposes 'Morning After' Pill to Prevent STIs'

 The CDC has moved to recommend doxycycline post-exposure prophylaxis (PEP) for gay and bisexual men and transgender women to prevent sexually transmitted infections (STIs).

With a growing body of evidence showing the antibiotic's effectiveness for the indication, the agency developed the proposed guidelineopens in a new tab or window and posted it to Regulations.gov on Mondayopens in a new tab or window, with a 45-day comment period.

Matthew Spinelli, MD, MAS, an infectious diseases physician at the University of California San Francisco, said the proposed guidance was "excellent news on many fronts."

"I am hopeful that the CDC guidance will be helpful in supporting more physicians to discuss doxy-PEP with their patients and to prescribe it," Spinelli told MedPage Today in an email. "The STI epidemic has been worsening year after year, so it is exciting to have a highly effective biomedical tool to prevent chlamydia, gonorrhea, and syphilis."

The guidelines come at a time when STIs are on the rise in the U.S., and "novel approaches are needed to address the STI epidemic, especially for populations disproportionately affected," the proposed guideline states.

More evidence has accumulated after a small study in 2015 showed pre-exposure prophylaxis (PrEP) with doxycycline reduced the incidence of infection with chlamydia and syphilis. While there have been no additional studies of doxycycline PrEP, CDC reviewed four new studies on doxycycline PEP for reducing STIs.

The open-label extension of the French IPERGAY studyopens in a new tab or window, involving men who have sex with men (MSM), showed that patients who received doxycycline PEP had reduced risk of acquiring chlamydia (HR 0.30, 95% CI 0.13-0.70) and syphilis (HR 0.27, 95% CI 0.07-0.98), though there was no difference in gonorrhea infections between the two groups.

In 2022, there were two studies, mainly in MSM, with favorable outcomes for doxycycline PEP. The randomized, open-label DoxyPEP trial in San Francisco and Seattle showed a significant reductionopens in a new tab or window in the incidence of chlamydia, gonorrhea, and syphilis. And the French ANRS DOXYVAC studyopens in a new tab or window was stopped early due to efficacy, with doxycycline significantly reducing the risk of gonorrhea (aHR 0.49, 95% CI 0.32-0.76), chlamydia (aHR 0.11, 95% CI 0.04-0.30), and syphilis (aHR 0.21, 95% CI 0.09-0.47), according to the guidance.

An open-label trial of women in Kenyaopens in a new tab or window, on the other hand, showed no reduction in STIs, but the CDC reviewers noted there were only two syphilis infections during the study, which also had adherence challenges.

"The limited evidence to support a recommendation in women is unfortunate," Spinelli said. "It is true that in the only study in women it was not effective, but we suspect this was related to lower adherence rather than true biological differences....We are hopeful that additional research will shed light on this topic and support a partial recommendation in women."

At the same time, CDC did raise cautions about the potential for antibiotic resistance with the treatment. Current data suggest "potential risks related to the development of resistance and impacts on the microbiome will need to be closely monitored after implementation of these guidelines," the guidance states.

Doxycycline is a broad-spectrum tetracycline antibiotic. Its most common adverse effects are photosensitivity and gastrointestinal symptoms including esophageal erosion and ulceration, according to the CDC. However, most adverse effects resolve when the medication is stopped.

Some of Spinelli's patients participated in the DoxyPEP trial, and his facility has been an early adopter of the treatment after results were presented at the 2022 International Aids Conference in Montreal.

"The clinics where I work have seen a decline in positive STI tests since doxy-PEP has been widely used," Spinelli said, adding that his patients are "excited to have access to this treatment and appreciative when I prescribe it."

"I think a positive STI diagnosis is an excellent time to discuss your patient's sexual health holistically, including offering HIV PrEP and doxy-PEP for STI prevention," Spinelli added.

https://www.medpagetoday.com/infectiousdisease/stds/106613